In small cap developmental biotech, we see a lot of creative financing, and when we understand how it works, we can profit from it. These types of biotech charts normally trade in a consistent ‘channel pattern.’ and when we spot…
Today at stockmatusow, we focus on a Bio-Pharmaceutical company with several near-term catalysts and give our thesis why we believe the company makes for a good long term speculative investment. Synergy Pharmaceuticals (SGYP) focuses on the development of drugs to…
Hi guys, Scott here with ya! Because so many people are asking me about $SLTM and what I believe is going on with them, I have made a public video for you to listen to my thesis regarding this matter.…
Recent developments in the medical device industry have paved the way for some strong achievements in many different sectors of the health care industry. With regards to heart failure, significant developments date back to the first implantable pacemaker successfully inserted…
Merger and acquisition rumors are heard on a daily basis throughout the market. Some have merit and turn out to be true, while others turn out to be false and without merit. Today, I will cover some companies that I…
n a bit more deliberate than Jazz, but is coming along nicely. Antares started its royalty deals with a gel based platform, one being a royalty deal with Actavis, Inc. (NYSE: ACT) (formely Watson Pharma) for topical oxybutynin gel. Oxybutynin…
Halozyme 60 Minute, 10 Day Chart Analysis As Of Close, 9/16/13 – Sentiment = Bullish
Scott’s Mid-Week Market Commentary For Week Aug 6 – 9/2013. $ONTX $INSM $AEGR $AUXL plus commentary on Market conditions and current chatter concerning the latest “terrorist threats,” and more!
Written by Scott Matusow, Mr.Matusow holds a position in the company featured in this article. Last week, Cubist Pharmaceuticals Inc. (CBST) agreed to buy Trius Therapeutics Inc. (TSRX) and Optimer Pharmaceuticals Inc. (OPTR) for as much as $1.62 billion. Cubist…
Recently, we have detailed companies that have released positive Phase III data because we believe several of these companies continue to be under speculation value. Companies who have strong management, cash, and a strong pipeline can be very profitable for…
